

Astellas, US Independent Medical Education and Pfizer Global Medical Grants

Call for Independent Medical Education Grant Applications Oncology – Prostate Cancer

Release Date: December 11, 2020

I. Background

Astellas and Pfizer (collectively, the Companies) are committed to supporting high quality, evidence-based independent medical education (IME) that seeks to improve the overall safety and quality of patient care and treatment. The intent of this Call for Grant Applications (CGA) is to encourage organizations to submit grant applications for independent CME/CE certified education designed to close knowledge gaps identified in the public healthcare landscape, drive measurable improvements in knowledge, competence and performance of healthcare professionals, and advance patient health outcomes. “Independent” means that the projects funded by the companies are the full responsibility of the recipient organization. The Companies do not have influence over any aspect of the supported projects and only ask for interim and final outcomes reports including a description of the impact of the projects.

When responding to this CGA, please adhere to the following principles in addition to the established guidelines for the Astellas IME grant application process. All applications must be submitted online through the Astellas Grant Management System, accessible at www.astellasgrants.com.

II. Eligibility

Geographic Scope:	United States Only
Applicant Eligibility Criteria:	<p>Eligible applicants include hospitals, academic medical centers and medical schools (Note: the CME Office must submit the request for accredited activities); national-level professional medical associations/societies; medical education companies; and publishers of medical and scientific publications.</p> <p>Collaborations within institutions (e.g., between departments and/or inter-professional), as well as between different institutions/organizations/associations are strongly encouraged. Please note all partners must have a relevant role and the requesting Organization must have a key role in the project. For programs offering continuing education credit, the requesting Organization must be the accredited grantee.</p>

III. Requirements

Date CGA Issued	December 11, 2020
Application Deadline	January 28, 2021
Anticipated Grant Decision Date	March 22, 2021
Clinical Area	Oncology – Prostate Cancer
Specific Education Gaps To Be Addressed	<p>The purpose of this CGA is to encourage Organizations to submit grant applications for independent CME/CE certified education designed to enhance understanding of increasingly complex treatment options and close knowledge gaps in earlier stages of prostate cancer. Knowledge gaps in prostate cancer which have been identified in the public healthcare landscape include:</p> <ul style="list-style-type: none"> • Recognizing and identifying the different prostate cancer disease states in the castration-sensitive prostate cancer (CSPC) setting. • Managing patients with prostate cancer following initial definitive therapy who then experience biochemical recurrence. • Navigating the lack of consensus in how to care for patients with prostate cancer in early stages of the disease. • Understanding the varying approaches to risk stratification of patients with CSPC in order to help predict likelihood of treatment success and improved outcomes.
How to Submit	<p>Please go to www.astellasgrants.com and sign in. First-time users should click “REGISTER NOW”.</p> <p>Select the following Area of Interest: Oncology – Prostate Cancer</p> <p>Requirements for submission: You must include “2020-CGA-02” in the “Activity Title” of your program’s online submission prior to the title.</p> <p>Complete all required sections of the online application and upload the Completed proposal.</p> <p>If you encounter any technical difficulties with the website, please click the “Need Support?” link at the bottom of the page.</p> <p>IMPORTANT: Be advised applications submitted through the wrong application type and/or submitted after the due date will not be reviewed.</p>

Target Audiences	<p>Urologists, medical oncologists, and other HCPs responsible for treatment decisions for patients with prostate cancer.</p> <p>Primary care providers and other members of a multi-disciplinary care team involved in management of AEs.</p>
Expected Approximate Monetary Range of Grant Applications	<p>Individual requests up to \$200,000 will be considered for funding. Funding of larger amounts will be considered for requests that include multiple activities, such as several live events, enduring activities, and supportive materials and tools. The amount of any grant funded by the Companies for any project may vary from the amount requested. Multi-supported initiatives are highly preferred to be submitted.</p> <p>Collaborations among multiple Organizations are encouraged. Activities with national reach will be prioritized.</p>

IV. Terms and Conditions

1. This CGA does not commit the Companies or their partners to award a grant or a grant of any particular amount if one is awarded, nor to pay any costs incurred in the preparation of a response to this request.
2. The Companies reserve the right to accept or reject any or all applications received as a result of this request, or to cancel this CGA in part or in its entirety at any time for any reason.
3. All communications about the CGA must be sent to Astellas IME at <http://www.astellasgrants.com/>. Applicants should not contact other departments within Astellas regarding this CGA. Failure to comply may affect the acceptance of your application.
4. The decision by the Companies to provide a grant will not be determined in a manner that takes into account the volume or value of any business otherwise generated between Astellas or Pfizer and any applicant.
5. Applicant shall have complete control over the content, development and implementation of the education programs and/or materials, including, if applicable, the selection of faculty. Any information provided as part of the program regarding any products, including, without limitation, Astellas and/or Pfizer products, shall be objective and based on scientific methods generally accepted in the medical community.
6. US Transparency Reporting

A. To enable Astellas to comply with its legal obligations, in the event that any payment or other transfer of value (hereinafter “payment” or “payments”) is provided, either directly or indirectly, to a covered recipient (as defined below) or to another individual or entity at the request or on behalf of a covered recipient, in connection with an approved grant request, Organization shall implement procedures to track the payments and shall report the payments to Astellas upon grant reconciliation and in accordance with any written instructions that Astellas may provide to Organization. Required reporting information includes, but shall not be limited to:

- a. Name and primary business address of covered recipient
- b. For physician covered recipient, NPI, state professional license number and specialty.
- c. Amount of payment
- d. Date of payment
- e. Form of payment
- f. Nature of payment

B. In addition to these tracking and reporting obligations, Organization shall inform such covered recipient at the time of payment that his/her/its acceptance of such payment may be disclosed in a report filed with government authorities by Astellas as required by law and that government authorities may make the reported information publicly available.

C. For purposes of this Agreement, the term “covered recipient” has the meaning ascribed to it in 42 C.F.R. § 403.902 and any similar state law which requires tracking and reporting of payments to a government agency for payment transparency purposes.

Frequently Asked Questions related to Astellas’ Sunshine Act Reporting Requirements are available on the website www.astellasgrants.com.